| Literature DB >> 28697343 |
Abstract
Two papers published recently in the New England Journal of Medicine describe the utility of abiraterone acetate, an androgen biosynthesis inhibitor, in the early treatment of metastatic prostate cancer. In addition to establishing a new standard of care, these two articles pose a number of important questions for future investigation.Entities:
Mesh：
Substances：
Year: 2017 PMID： 28697343 DOI： 10.1016/j.ccell.2017.06.007
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743